QQQ   326.09 (+1.35%)
AAPL   167.34 (+1.20%)
MSFT   285.29 (+0.84%)
META   175.06 (+4.76%)
GOOGL   119.88 (+2.05%)
AMZN   143.10 (+1.63%)
TSLA   903.07 (+4.46%)
NVDA   181.69 (-4.32%)
NIO   20.70 (+2.37%)
BABA   92.20 (-0.39%)
AMD   101.27 (-1.02%)
MU   62.37 (-0.14%)
T   18.19 (-0.87%)
CGC   3.09 (+14.44%)
GE   75.89 (+2.06%)
F   15.77 (+3.07%)
DIS   110.36 (+3.50%)
AMC   24.97 (+12.58%)
PYPL   98.66 (+3.50%)
PFE   49.27 (+0.00%)
NFLX   237.87 (+4.89%)
QQQ   326.09 (+1.35%)
AAPL   167.34 (+1.20%)
MSFT   285.29 (+0.84%)
META   175.06 (+4.76%)
GOOGL   119.88 (+2.05%)
AMZN   143.10 (+1.63%)
TSLA   903.07 (+4.46%)
NVDA   181.69 (-4.32%)
NIO   20.70 (+2.37%)
BABA   92.20 (-0.39%)
AMD   101.27 (-1.02%)
MU   62.37 (-0.14%)
T   18.19 (-0.87%)
CGC   3.09 (+14.44%)
GE   75.89 (+2.06%)
F   15.77 (+3.07%)
DIS   110.36 (+3.50%)
AMC   24.97 (+12.58%)
PYPL   98.66 (+3.50%)
PFE   49.27 (+0.00%)
NFLX   237.87 (+4.89%)
QQQ   326.09 (+1.35%)
AAPL   167.34 (+1.20%)
MSFT   285.29 (+0.84%)
META   175.06 (+4.76%)
GOOGL   119.88 (+2.05%)
AMZN   143.10 (+1.63%)
TSLA   903.07 (+4.46%)
NVDA   181.69 (-4.32%)
NIO   20.70 (+2.37%)
BABA   92.20 (-0.39%)
AMD   101.27 (-1.02%)
MU   62.37 (-0.14%)
T   18.19 (-0.87%)
CGC   3.09 (+14.44%)
GE   75.89 (+2.06%)
F   15.77 (+3.07%)
DIS   110.36 (+3.50%)
AMC   24.97 (+12.58%)
PYPL   98.66 (+3.50%)
PFE   49.27 (+0.00%)
NFLX   237.87 (+4.89%)
QQQ   326.09 (+1.35%)
AAPL   167.34 (+1.20%)
MSFT   285.29 (+0.84%)
META   175.06 (+4.76%)
GOOGL   119.88 (+2.05%)
AMZN   143.10 (+1.63%)
TSLA   903.07 (+4.46%)
NVDA   181.69 (-4.32%)
NIO   20.70 (+2.37%)
BABA   92.20 (-0.39%)
AMD   101.27 (-1.02%)
MU   62.37 (-0.14%)
T   18.19 (-0.87%)
CGC   3.09 (+14.44%)
GE   75.89 (+2.06%)
F   15.77 (+3.07%)
DIS   110.36 (+3.50%)
AMC   24.97 (+12.58%)
PYPL   98.66 (+3.50%)
PFE   49.27 (+0.00%)
NFLX   237.87 (+4.89%)
NASDAQ:OGI

OrganiGram - OGI Stock Forecast, Price & News

$1.17
+0.06 (+5.41%)
(As of 08/8/2022 10:03 AM ET)
Add
Compare
Today's Range
$1.10
▼
$1.17
50-Day Range
$0.92
▼
$1.16
52-Week Range
$0.90
▼
$2.92
Volume
13,826 shs
Average Volume
4.43 million shs
Market Capitalization
$367.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.05

OrganiGram MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
160.7% Upside
$3.05 Price Target
Short Interest
Healthy
3.20% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.09) to ($0.05) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

756th out of 1,293 stocks

Pharmaceutical Preparations Industry

366th out of 619 stocks

See Top Rated MarketRank™ Stocks Here
OGI stock logo

About OrganiGram (NASDAQ:OGI) Stock

Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including cannabis flowers, cannabis oils, and vaporizers for civilian patients and veterans; adult use recreational cannabis under the Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour brands; and cannabis edibles products and concentrates. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on OGI shares. Stifel Nicolaus decreased their target price on OrganiGram from C$2.25 to C$1.50 in a research report on Friday, July 15th. Atb Cap Markets raised OrganiGram from a "sector perform" rating to an "outperform" rating in a research report on Tuesday, April 12th. Finally, Alliance Global Partners decreased their target price on OrganiGram from C$2.25 to C$1.50 in a research report on Friday, July 15th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $3.04.

OrganiGram Trading Up 0.9 %

Shares of OGI Stock traded up $0.01 on Friday, hitting $1.11. 997,733 shares of the stock were exchanged, compared to its average volume of 2,346,591. The firm has a market capitalization of $348.22 million, a PE ratio of -12.33 and a beta of 0.62. OrganiGram has a one year low of $0.90 and a one year high of $2.92. The firm's 50 day moving average is $1.04 and its two-hundred day moving average is $1.32.

Receive OGI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OrganiGram and its competitors with MarketBeat's FREE daily newsletter.

OGI Stock News Headlines

July 27, 2022 | streetinsider.com
Top Canadian Cannabis Stocks To Watch Before August - StreetInsider.com
July 24, 2022 | americanbankingnews.com
OrganiGram Holdings Inc. (NASDAQ:OGI) Forecasted to Earn FY2024 Earnings of ($0.01) Per Share
July 19, 2022 | americanbankingnews.com
OrganiGram (NASDAQ:OGI) PT Lowered to C$1.50 at Alliance Global Partners
July 17, 2022 | americanbankingnews.com
Raymond James Analysts Cut Earnings Estimates for OrganiGram Holdings Inc. (NASDAQ:OGI)
July 14, 2022 | fool.com
Here's What Moved Sundial Growers, Organigram, and Canopy Growth Stocks Today - The Motley Fool
July 14, 2022 | ca.investing.com
Organigram Holdings Reports Q2 Net Loss of $2.79M By Investing.com - Investing.com Canada
July 14, 2022 | seekingalpha.com
Organigram revenue of $38.12M beats by $12.05M, sees Q4 revenue higher than Q3 - Seeking Alpha
July 4, 2022 | fool.ca
With the Cannabis Industry Trading Ultra-Cheap, Organigram Stock Looks Like a Screaming Buy! - The Motley Fool Canada
July 1, 2022 | ft.com
We should have limited empathy for the Big Boss resignation - Financial Times
June 24, 2022 | benzinga.com
Organigram Reaches Proposed Settlement In 2016 Class Action - Benzinga - Benzinga
June 7, 2022 | investing.com
As Cannabis Stocks Continue To Tank, Look At Sales Growth For Turnaround Sign - Investing.com
June 6, 2022 | finance.yahoo.com
Nextleaf Solutions (CSE: OILS) (OTCQB: OILFF) to Webcast Live June 7th at VirtualInvestorConferences.com - Yahoo Finance
May 13, 2022 | benzinga.com
Organigram Q2 Fiscal 2022 Revenue Grows 117% YoY Primaraly Because Of This - Benzinga - Benzinga
April 27, 2022 | benzinga.com
Cantor Fitzgerald Maintains Overweight on OrganiGram Holdings, Lowers Price Target to C$3.7 - Benzinga
April 21, 2022 | nasdaq.com
Happy 420 Day! Buy This Top Pot Stock Now to Celebrate Later. - Nasdaq
April 20, 2022 | marketwatch.com
Leafly CEO rings Nasdaq bell on cannabis holiday - MarketWatch
April 20, 2022 | fool.com
3 Top Pot Stocks to Buy Right Now - The Motley Fool
April 14, 2022 | fool.com
Why OrganiGram Holdings Shares Rose 20.9% This Week - The Motley Fool
April 14, 2022 | nasdaq.com
3 Steps to Claiming the $4,194 Max Monthly Social Security Benefit - Nasdaq
April 14, 2022 | nasdaq.com
Why Shares in Delta Air Lines Continued Their Ascent Today - Nasdaq
April 14, 2022 | finance.yahoo.com
Why OrganiGram Holdings Shares Rose 20.9% This Week
April 12, 2022 | baystreet.ca
Demand for Cannabinol (CBN) Could Create a Massive Opportunity - Baystreet.ca
April 11, 2022 | nasdaq.com
Pre-Market Earnings Report for April 12, 2022 : ACI, KMX, OGI - Nasdaq
April 1, 2022 | seekingalpha.com
TLRY, CGC stocks higher as House clears Marijuana legalization bill (NASDAQ:TLRY) - Seeking Alpha
March 27, 2022 | benzinga.com
Here's Why OrganiGram Shares Are Rising
See More Headlines
Receive OGI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OrganiGram and its competitors with MarketBeat's FREE daily newsletter.

OGI Company Calendar

Last Earnings
7/12/2021
Today
8/08/2022
Fiscal Year End
8/31/2022
Next Earnings (Estimated)
11/22/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OGI
CUSIP
N/A
CIK
1620737
Web
www.organigram.ca
Phone
(844) 644-4726
Fax
N/A
Employees
841
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.05
High Stock Price Forecast
$5.30
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+160.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.09)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-103,090,000.00
Net Margins
-27.78%
Pretax Margin
-28.91%
Return on Equity
-11.81%
Return on Assets
-10.35%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.17
Quick Ratio
3.06

Sales & Book Value

Annual Sales
$62.43 million
Price / Sales
5.88
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.26 per share
Price / Book
0.93

Miscellaneous

Outstanding Shares
313,708,000
Free Float
N/A
Market Cap
$367.04 million
Optionable
Not Optionable
Beta
0.62

Key Executives

  • Mr. Derrick W. West CPA (Age 55)
    CPA, (CA), Chief Financial Officer
    Comp: $244.82k
  • Ms. Helen Martin (Age 44)
    Chief Legal Officer & Corp. Sec.
    Comp: $229.3k
  • Mr. Gregory Engel (Age 57)
    Special Advisor
    Comp: $458.69k
  • Mr. Timothy Emberg
    Chief Revenue Officer
  • Mr. Paolo De Luca C.A. (Age 49)
    C.F.A, Chief Strategy Officer
    Comp: $241.58k
  • Ms. Beena G. Goldenberg (Age 59)
    CEO & Director
  • Ms. Nathalie Batten
    VP of Operations
  • Amy Schwalm
    VP of Investor Relations
  • Ms. Megan Amber McCrae
    Sr. VP of Marketing & Communications
  • Tina Shannon
    VP of HR

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













OGI Stock - Frequently Asked Questions

Should I buy or sell OrganiGram stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OrganiGram stock.
View analyst ratings for OrganiGram or view top-rated stocks.

What is OrganiGram's stock price forecast for 2022?

6 Wall Street analysts have issued 12 month price targets for OrganiGram's shares. Their OGI stock forecasts range from $1.50 to $5.30. On average, they predict OrganiGram's stock price to reach $3.05 in the next twelve months. This suggests a possible upside of 174.8% from the stock's current price.
View analysts' price targets for OrganiGram or view top-rated stocks among Wall Street analysts.

How has OrganiGram's stock performed in 2022?

OrganiGram's stock was trading at $1.75 at the beginning of 2022. Since then, OGI shares have decreased by 36.6% and is now trading at $1.11.
View the best growth stocks for 2022 here.

When is OrganiGram's next earnings date?

OrganiGram is scheduled to release its next quarterly earnings announcement on Tuesday, November 22nd 2022.
View our earnings forecast for OrganiGram.

How were OrganiGram's earnings last quarter?

OrganiGram Holdings Inc. (NASDAQ:OGI) issued its quarterly earnings data on Monday, July, 12th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.02. The firm had revenue of $16.55 million for the quarter, compared to analysts' expectations of $13.95 million. OrganiGram had a negative net margin of 27.78% and a negative trailing twelve-month return on equity of 11.81%.

What other stocks do shareholders of OrganiGram own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OrganiGram investors own include KushCo (KSHB), Auxly Cannabis Group (CBWTF), Supreme Cannabis (SPRWF), Medical Marijuana (MJNA), CNBX Pharmaceuticals (CNBX), MariMed (MRMD), Aurora Cannabis (ACB), EVIO (EVIO) and Gran Tierra Energy (GTE).

What is OrganiGram's stock symbol?

OrganiGram trades on the NASDAQ under the ticker symbol "OGI."

Who are OrganiGram's major shareholders?

OrganiGram's stock is owned by a variety of retail and institutional investors. Top institutional investors include Mirae Asset Global Investments Co. Ltd. (1.24%), Merlin Capital LLC (0.67%), Connor Clark & Lunn Investment Management Ltd. (0.18%), TD Asset Management Inc. (0.07%), Walker Asset Management LLC (0.02%) and Lindbrook Capital LLC (0.02%).

How do I buy shares of OrganiGram?

Shares of OGI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OrganiGram's stock price today?

One share of OGI stock can currently be purchased for approximately $1.11.

How much money does OrganiGram make?

OrganiGram (NASDAQ:OGI) has a market capitalization of $348.22 million and generates $62.43 million in revenue each year. The company earns $-103,090,000.00 in net income (profit) each year or ($0.09) on an earnings per share basis.

How many employees does OrganiGram have?

OrganiGram employs 841 workers across the globe.

How can I contact OrganiGram?

OrganiGram's mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The official website for OrganiGram is www.organigram.ca. The company can be reached via phone at (844) 644-4726.

This page (NASDAQ:OGI) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.